GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » Current Accrued Expense

Launxp Biomedical Co (ROCO:6876) Current Accrued Expense : NT$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Launxp Biomedical Co Current Accrued Expense?

Launxp Biomedical Co's Current Accrued Expense for the quarter that ended in Dec. 2024 was NT$0.00 Mil.


Launxp Biomedical Co Current Accrued Expense Historical Data

The historical data trend for Launxp Biomedical Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Launxp Biomedical Co Current Accrued Expense Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
- - - - -

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only - - - - -

Launxp Biomedical Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Launxp Biomedical Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Launxp Biomedical Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Launxp Biomedical Co Business Description

Traded in Other Exchanges
N/A
Address
10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.

Launxp Biomedical Co Headlines

No Headlines